<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04619277</url>
  </required_header>
  <id_info>
    <org_study_id>USH-20-004</org_study_id>
    <secondary_id>USH-20-004</secondary_id>
    <nct_id>NCT04619277</nct_id>
  </id_info>
  <brief_title>Impact of Drug-coated Balloon Treatment in de Novo Coronary Lesion</brief_title>
  <official_title>Impact of Drug-coated Balloon Treatment in de Novo Coronary Lesion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ulsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ulsan Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is the international multicenter registry for drug-coated balloon treatment for de&#xD;
      novo coronary lesion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is lots of evidence that DCBs result in lower rates of restenosis, thrombosis, and&#xD;
      better long-term outcomes when used for PCI of in-stent restenosis (ISR) compared to plain&#xD;
      old balloon angioplasty (POBA) or additional stenting with drug-eluting stent (DES). DCB-only&#xD;
      approach studies for de novo coronary lesion cases are scarce, but a recent registry data&#xD;
      suggested it was a feasible and well-tolerated treatment method if the pre-dilation result is&#xD;
      good. Therefore, the aim of this study was to evaluate the safety and efficacy in terms of&#xD;
      angiographic and clinical outcomes of a DCB-only approach for de novo coronary lesions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2011</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Major adverse cardiac events at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Primary endpoint is major adverse cardiac events (MACE is a composite of cardiac death, non-fatal myocardial infarction, target-vessel revascularization and major bleeding [BARC type 3 to 5]) at 12 months.&#xD;
Cardiac death: Any death due to proximate cardiac cause (eg, myocardial infarction, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, and all procedure-related deaths, including those related to concomitant treatment, will be classified as cardiac death.&#xD;
Target vessel Revascularization: TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic and clinical outcomes</measure>
    <time_frame>12, 24, 36 months</time_frame>
    <description>MACE at 12, 24, 36 months&#xD;
The single components of the primary endpoint after 12, 24, 36 months. Bleeding Academic Research Consortium (BARC) type 2 to 5 bleeding after 12, 24, 36 months.1 (All events will be adjudicated by an independent Critical Events Committee).&#xD;
Possible, probable, and definite stent thrombosis defined according to the ARC criteria after 12, 24, 36 months.&#xD;
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation&#xD;
Cost-effectiveness of DCB vs. DES after 12, 24, 36 months.&#xD;
All-cause death ⑥ Stroke (ischemic and hemorrhagic)&#xD;
Angina severity measured with Seattle Angina Questionnaires at 12, 24 months&#xD;
Total procedure time, fluoroscopy time, contrast volume, number of stents used ⑨ DAPT duration ⑩ Periprocedural MI rate ⑪ Sex difference in MACE between DCB vs. DES ⑫ Comparison of MACE between DCB vs. DES in DM patients</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Drug-coated Balloon</condition>
  <arm_group>
    <arm_group_label>Ulsan Medical Center</arm_group_label>
    <description>Division of Cardiology, Department of Internal Medicine, Ulsan Medical Center, Ulsan, South Korea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Queen Elizabeth Hospital</arm_group_label>
    <description>Cardiology Department and Clinical Research Center, Queen Elizabeth Hospital II, Kota Kinabalu, Malaysia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pecking University Shougand Hospital</arm_group_label>
    <description>Department of Cardiology, Peking University Shougang Hospital, Peking, China</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulsan University Hospital</arm_group_label>
    <description>Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kangwon National University School of Medicine</arm_group_label>
    <description>Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, South Korea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Korea University Guro Hospital</arm_group_label>
    <description>Cardiovascular Center, Department of Cardiology, Korea University Guro Hospital, Seoul, South Korea</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug-coated balloon</intervention_name>
    <description>drug-coated balloon</description>
    <arm_group_label>Kangwon National University School of Medicine</arm_group_label>
    <arm_group_label>Korea University Guro Hospital</arm_group_label>
    <arm_group_label>Pecking University Shougand Hospital</arm_group_label>
    <arm_group_label>Queen Elizabeth Hospital</arm_group_label>
    <arm_group_label>Ulsan Medical Center</arm_group_label>
    <arm_group_label>Ulsan University Hospital</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        It is a international multicenter registry study conducted at 4 centers (Queen Elizabeth&#xD;
        Hospital II, Peking Shougang Hospital, Ulsan Medical Center, and Ulsan University Hospital)&#xD;
        expert in patients with de novo coronary lesion who received DCB treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - de novo coronary artery disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unstable hemodynamics at presentation&#xD;
&#xD;
          -  life expectancy &lt;1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo-Jin Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eun-Seok Shin</last_name>
    <email>sesim1989@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ulsan Medical Center</name>
      <address>
        <city>Ulsan</city>
        <zip>44686</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun-Seok Shin</last_name>
      <email>sesim1989@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ulsan Medical Center</investigator_affiliation>
    <investigator_full_name>Eun-Seok Shin</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

